Pilot study to develop prototype agentic AI sub-system for initial validation screening of targets identified using AI predictive genomics platform, Nomaly
Funding provided jointly by Innovate UK and Empirical Ventures through Innovate UK Growth Catalyst – Investor Partnership grant programme
Cambridge, UK, 8 September 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive approach to uncover new drug targets, today announced it has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical…
StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to support seamless human pluripotent stem cell culture—from iPSC establishment through expansion, and from research to clinical manufacturing. Its simplified one-bottle formulation streamlines process development while reducing workflow complexity and contamination risk.
In rigorous testing - StemFit Basic04CT demonstrated improved workflow efficiency, enhanced ease of adoption and the lowest cost per well compared to other popular xeno-free stem cell culture products.
Dr Philipp…
Community café and flexible meeting space welcomes local groups, residents and businesses alike
Glasgow, 7 September, 2026
Since opening earlier this year, Glasgow's pioneering Health Innovation Hub (HiH) has both been home to world-class life science innovation and opened its doors to the local community. In recent months representatives from over 20 different organisations and local groups have utilised the community cafe space.
Officially opened in March 2026, the purpose-built facility has become home to pioneering organisations including Chemify, the HealthTech Innovation &…
9am BST, Stevenage, 7 Sep 2026
The Board of SBC is delighted to announce the promotion of Andrew Waters from his current position of Chief Financial Officer & Interim CEO to the position of Chief Executive Officer.
Andrew has a First Class Physics degree from Imperial College, is an FCA Chartered Accountant and has worked almost his whole career within the Life Sciences industry. After 4 years at PwC London, Andrew spent 16 years at GSK in a number of positions across R&D and the commercial business including time working overseas in US, Denmark and Netherlands. …
Helping high-throughput laboratories increase multiplexing capacity and maximise sequencing throughput without changing established workflows
Oxford, UK, September 2026.
OGT, a leading global provider of genomic research and diagnostic solutions, today announced the expansion of its SureSeq™ Universal NGS Unique Dual Index (UDI) range, enabling laboratories to multiplex up to 384 uniquely indexed samples in a single sequencing run. Compatible with existing SureSeq™ workflows and software, expanded UDI capabilities provide a straightforward path for laboratories looking to scale throughput…
LONDON, UK – September 3, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for NRG Therapeutics Ltd. ("NRG") and is pleased to announce the placement of Claus Sundgreen, M.D. as Chief Medical Officer (CMO).NRG Therapeutics is a clinical-stage neuroscience company developing novel disease-modifying therapeutics that restore mitochondrial health in neurodegenerative diseases. Its lead clinical asset, NRG5051, is a first-in-class, orally bioavailable and CNS-penetrant next-…
Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases
Two UK biotechs developing novel approaches to treating diseases such as psoriasis and Parkinson’s have secured investment and strategic support from Medicines Discovery Catapult (MDC) to accelerate their progress.
Flip Therapeutics and Nascent Therapeutics will each receive £500,000 in funding made available by Innovate UK as part of a scheme that enabled Catapults to invest in high-potential companies.
Alongside the investment, MDC, which…
We’re preparing the next edition of One Nucleus Highlights—our A4 printed and digital publication launching 9 November 2026, at BIO-Europe.
To reach our life science ecosystem with your expertise, you can submit a thought-leadership piece on a key theme felt to be shaping our industry and wider trends in the sector. Alternatively, you could place an advert to be seen in such a context in the eyes of your key customers.
Why Contribute?
Prime visibility – distributed at our high-profile in-person events, showcased on our website, and amplified through a social media campaign to…
For years, the instinct in drug discovery was simple: when a decision is hard, get more data. But that instinct has stopped paying off. The binding constraint today isn't volume—it’s fragmentation. Our latest white paper explores why the most valuable signals are hiding in the space between datasets that were never built to speak to one another.
Stop collecting and start connecting. Read the full analysis here: https://www.digital-science.com/lp/data-integration-challenge/
#DrugDiscovery #DataStrategy #BioTech #DigitalScience
In life sciences, "feeling" ready for the future isn’t a strategy—it’s a risk. Are you actually leading the field? Most organizations are busy, but few know if they’re actually keeping pace with their peers.
We’re officially launching The Innovation Readiness Index: a diagnostic designed to stop the guesswork. We benchmark your capabilities across the 5 pillars that matter:
👉 Trust & Outcomes
👉 Governance & Flow
👉 AI Readiness
Participate in a brief diagnostic interview and receive a personalized gap analysis in a private 30-minute executive briefing.
🔗 See where you stand:…